Cargando…

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

PURPOSE: Breast cancer stem cells (CSCs) are responsible for the initiation, recurrence, and metastasis of breast cancer. Sufficient evidence has established that breast cancer cells can spontaneously turn into breast CSCs. Thus, it is essential to simultaneously target breast CSCs and cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jun, Xu, Wenqing, Yuan, Xiaoli, Chen, Huaiwen, Song, Hao, Wang, Bingquan, Han, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609783/ https://www.ncbi.nlm.nih.gov/pubmed/29075110 http://dx.doi.org/10.2147/IJN.S144184

Ejemplares similares

Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells
por: Yu, Zuochong, et al.
Publicado: (2018)

Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133(+) osteosarcoma cancer stem cells
por: Ni, Miaozhong, et al.
Publicado: (2015)

Redox Potential Ultrasensitive Nanoparticle for the Targeted Delivery of Camptothecin to HER2-Positive Cancer Cells
por: K.C., Remant Bahadur, et al.
Publicado: (2014)

HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells
por: Yamaguchi, Haruka, et al.
Publicado: (2018)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

GE11 Modified PLGA/TPGS Nanoparticles Targeting Delivery of Salinomycin to Breast Cancer Cells
por: Li, Kaichun, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Lipid–Polymer Hybrid Nanoparticle-Based Combination Treatment with Cisplatin and EGFR/HER2 Receptor-Targeting Afatinib to Enhance the Treatment of Nasopharyngeal Carcinoma
por: Fu, Dehui, et al.
Publicado: (2021)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
por: Mann, K, et al.
Publicado: (2016)

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells
por: Palanca-Wessels, Maria C., et al.
Publicado: (2016)

Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment
por: Eljack, Sahar, et al.
Publicado: (2022)

Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles
por: Gao, Jie, et al.
Publicado: (2019)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
por: Hosonaga, Mari, et al.
Publicado: (2014)

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment
por: Gu, Shenda, et al.
Publicado: (2018)

The Molecular Basis for Inhibition of Stemlike Cancer Cells by Salinomycin
por: Huang, Xiaoli, et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
por: Niza, Enrique, et al.
Publicado: (2019)

Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer
por: Yang, Xiaojing, et al.
Publicado: (2023)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells
por: Wang, Qin, et al.
Publicado: (2021)

The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells
por: Ram, Sripad, et al.
Publicado: (2014)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
por: Sitia, Leopoldo, et al.
Publicado: (2022)

PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death
por: Shipunova, Victoria Olegovna, et al.
Publicado: (2021)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis
por: Zhou, Chenfei, et al.
Publicado: (2018)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems
por: Balgobind, Adhika, et al.
Publicado: (2023)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells
por: DONG, ZHONGYUN, et al.
Publicado: (2014)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
por: Sun, Jiangang, et al.
Publicado: (2022)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_n76tfgg2pjsvravv1sajg939pb